Fisher Asset Management LLC Trims Stake in Sanofi (NASDAQ:SNY)

Fisher Asset Management LLC lowered its position in Sanofi (NASDAQ:SNY) by 6.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,511,027 shares of the company’s stock after selling 848,083 shares during the quarter. Fisher Asset Management LLC owned about 0.49% of Sanofi worth $603,407,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Abel Hall LLC increased its stake in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after buying an additional 194 shares during the period. PDS Planning Inc increased its stake in Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after buying an additional 200 shares during the period. Financial Advocates Investment Management increased its stake in Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after buying an additional 206 shares during the period. Angeles Investment Advisors LLC increased its stake in Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after buying an additional 210 shares during the period. Finally, Keudell Morrison Wealth Management increased its stake in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after buying an additional 217 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Up 0.6 %

NASDAQ:SNY opened at $54.47 on Friday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a market capitalization of $138.24 billion, a P/E ratio of 21.88, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company’s 50-day simple moving average is $51.65 and its 200-day simple moving average is $52.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.